{"id":"W4282961029","doi":"10.1158/1538-7445.am2022-ct236","title":"Abstract CT236: INTERLINK-1: A phase 3, randomized, double-blind, placebo-controlled, multicenter, global study of monalizumab in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma previously treated with an immune checkpoint inhibitor","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cetuximab; Medicine; Pembrolizumab; Head and neck squamous-cell carcinoma; Internal medicine; Nivolumab; Oncology; Cancer; Discontinuation; Head and neck cancer; Phases of clinical research; Chemotherapy; Immunotherapy; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002152816,0.002998712,0.003499036,0.0006058274,0.0007242188,0.001819688,0.001648627,0.002327444,0.009564358],"category_scores_gemma":[0.001046343,0.0009435626,0.002416749,0.000654454,0.001370403,0.001254982,0.0004687206,0.004238139,0.002023078],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00118269,"about_ca_system_score_gemma":0.002049447,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001662285,"about_ca_topic_score_gemma":0.003618493,"domain_scores_codex":[0.9992999,0.0003127922,0.00003956174,0.0001608032,0.00007634559,0.0001105672],"domain_scores_gemma":[0.9992878,0.00008335215,0.0001814922,0.00004560905,0.0000668203,0.0003348636],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9458729,0.02309829,0.0004903295,0.00124009,0.002172492,0.00005461203,0.00007609642,0.0003608262,0.009159695,0.0001027773,0.002010993,0.01536097],"study_design_scores_gemma":[0.906849,0.08968823,0.001163364,0.00003258183,0.0005020952,0.00003024379,0.00001560383,0.0002659154,0.0006055814,0.00006583086,0.0007621743,0.00001932594],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9655347,0.01286682,0.001378153,0.001322488,0.001083871,0.01084757,0.003043855,0.0005826345,0.003339848],"genre_scores_gemma":[0.9697739,0.005770705,0.00264543,0.002542388,0.0008058117,0.009539888,0.002744869,0.00009428169,0.006082821],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009564358,"threshold_uncertainty_score":0.03199601,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04767354555543456,"score_gpt":0.3697721642947267,"score_spread":0.3220986187392921,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}